Boston, MA -- (SBWIRE) -- 07/21/2012 -- COPD is a growing market with a dynamic pipeline aiming to address unmet needs. A number of pipeline products threaten established drug classes. Once-daily bronchodilator combinations in particular are expected to offer a novel treatment option with high clinical and commercial potential and a number of companies are racing to be the first to reach the market.

Report Scope

- Access Datamonitor's independent clinical and commercial assessment of marketed brands and key pipeline agents for COPD.
- Understand what it takes to differentiate a product in COPD treatment and how the pipeline threatens current market leaders.
- Assess how pipeline products compare to each other and how they will compete with established therapies.
- Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.

Report Highlights

As the first once-daily LAMA, Spiriva (tiotropium; Boehringer Ingelheim) has become the clear gold-standard monotherapy for COPD, with widespread use across all disease severities. A number of novel LAMAs are being developed, but these will struggle to compete with Spiriva, which has had years to develop a loyal physician and patient base.

View Full Report Details and Table of Contents

Significant developments are expected during 2012 as numerous promising candidates are close to reaching the COPD market. Almirall's LAMA Eklira (aclidinium) is under review in the US and EU with a decision expected later in 2012. If successful, Eklira could pose the first direct threat to Spiriva (tiotropium; Boehringer Ingelheim).

GlaxoSmithKline and Novartis are set to go head-to-head in a number of key drug classes for COPD, including the first once-daily ICS/LABA and LABA/LAMA combinations. With Phase III trials complete and plans to file in mid-2012, GlaxoSmithKline's Relovair (fluticasone furoate/vilanterol) is on track to become the first approved once-daily ICS/LABA

Reasons to Get this Report

- How do marketed treatments of COPD compare to one another and where will pipeline agents fit in?
- How are key players like Boehringer Ingelheim and GlaxoSmithKline protecting their market position in the face of increasing competition?
- Which pipeline products will need to compete with currently established treatments, and which can be positioned as add-on therapies?
- How is COPD treatment expected to change as novel therapies move through the pipeline?

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries
- Product Profiles: Colorectal Cancer - New drug combinations and label expansions will increase competition
- Product Profiles: Asthma - Key companies act to maintain dominance
- Product Profiles: Allergic Rhinitis - Heavily genericized market sees areas of innovation
- MediciNova, Inc. - Product Pipeline Review - H2 2011
- Product Profiles: Disease Modification in Rheumatoid Arthritis - Game-changing therapy close to market
- Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2011
- Product Profiles: Depression - Next generation vies for second-line patients
- Inovio Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011
- BTG plc - Product Pipeline Review - H2 2011